CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the ...

An approach using engineered small extracellular vesicles from NK cells to DR5 could be a promising strategy for solid tumors ...

A groundbreaking study from Baylor College of Medicine explores how two types of CAR T cells target cancer, shedding light on ...

Scientists from A*STAR Genome Institute of Singapore (A*STAR GIS) have uncovered that a key enzyme—P4HA1 prolyl hydroxylase, ...

KJ-C2219 is developed based on CARsgen's THANK-u Plus platform and is designed for the treatment of hematologic malignancies and autoimmune diseases. An investigator-initiated trial is ongoing in ...

The first patient with relapsed/refractory acute myeloid leukemia has received KJ-C2320, an allogeneic CAR T-cell therapy ...

A study published in Science Advances shares new insights into how two of the most common types of chimeric antigen receptor ...

A new type of cell-based immunotherapy shows promise for B-cell lymphomas and - due to innovations in manufacturing - could make future cellular immunotherapies less expensive and more accessible to ...

A study explores the molecular dynamics of CD28.ζ-CAR and 4-1BB.ζ-CAR T cells at the immune synapse, where CAR T cells bind ...

After 14 years of cancer treatment, and with few options left, CAR T-cell therapy puts a patient lymphoma into remission.

For patients with relapsed/refractory large B-cell lymphoma, access to lifesaving CD19-directed chimeric antigen receptor (CAR) T-cell therapy may be limited by post-infusion monitoring protocols ...